Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Yasuhisa Mori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9928-3933; OpenAlex author ID A5112004707. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2013: 3 papers · 2014: 3 papers · 2015: none · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… Co-author DOI 10.1002/ags3.70090↗
  2. Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17792↗
  3. Extensive (subtotal) distal pancreatectomy for pancreatic ductal adenocarcinoma: a propensity score matched cohort study of short- and long-term outcomes compa… Co-author DOI 10.1007/s00423-022-02453-4↗
  4. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Co-author DOI 10.1007/s00595-020-02123-2↗
  5. Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced-stage cancer? Co-author DOI 10.1002/ags3.12340↗
  6. High-risk lesions in the remnant pancreas: fate of the remnant pancreas after pancreatic resection for pancreatic cancer and intraductal papillary mucinous neo… Co-author DOI 10.1007/s00595-019-01852-3↗
  7. Early Detection of Pancreatic Cancer: Role of Biomarkers in Pancreatic Fluid Samples. First author DOI 10.3390/diagnostics10121056↗
  8. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07269-z↗
  9. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. Co-author DOI 10.1245/s10434-019-07309-8↗
  10. Surveillance of patients with intraductal papillary mucinous neoplasm with and without pancreatectomy with special reference to the incidence of concomitant pa… Co-author DOI 10.1016/j.surg.2017.09.040↗
  11. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6761-6↗
  12. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.10.035↗
  13. S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000940↗
  14. Intraoperative irrigation cytology of the remnant pancreas to detect remnant distinct pancreatic ductal adenocarcinoma in patients with intraductal papillary m… Co-author DOI 10.1016/j.surg.2013.06.059↗
  15. Profiling of autoantibodies in sera of pancreatic cancer patients. Co-author DOI 10.1245/s10434-014-3574-0↗
  16. Hepaticocholecystojejunostomy as effective palliative biliary bypass for unresectable pancreatic cancer. Co-author PMID 24895820↗
  17. Role of endoscopic retrograde pancreatography for early detection of pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm … Co-author DOI 10.1007/s00534-012-0541-7↗
  18. A minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma using biomarkers in duodenal juice. Co-author DOI 10.1097/mpa.0b013e3182649979↗
  19. Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer. Co-author DOI 10.1016/j.jss.2011.11.714↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takao Ohtsuka · 18 shared papers, 2013–2025 · strength 1.60
  2. Masafumi Nakamura · 13 shared papers, 2013–2026 · strength 1.30
  3. Kohei Nakata · 9 shared papers, 2017–2025 · strength 1.07
  4. Yoshinao Oda · 10 shared papers, 2014–2025 · strength 0.87
  5. Yoshihiro Miyasaka · 8 shared papers, 2017–2025 · strength 0.86
  6. Noboru Ideno · 8 shared papers, 2013–2025 · strength 0.75
  7. Ryuichiro Kimura · 4 shared papers, 2019–2025 · strength 0.55
  8. Naoki Ikenaga · 3 shared papers, 2021–2026 · strength 0.52
  9. Masafumi Nakamura · 5 shared papers, 2017–2022 · strength 0.49
  10. Kenoki Ohuchida · 6 shared papers, 2013–2021 · strength 0.48
  11. Ryota Matsuda · 3 shared papers, 2019–2020 · strength 0.33
  12. Yusuke Watanabe · 2 shared papers, 2021–2022 · strength 0.29
  13. Masao Tanaka · 7 shared papers, 2013–2017 · strength 0.28
  14. Shingo Kozono · 2 shared papers, 2013–2026 · strength 0.26
  15. Toru Hisaka · 1 shared paper, 2026 · strength 0.23
  16. Teijiro Hirashita · 1 shared paper, 2026 · strength 0.23
  17. Hiromitsu Hayashi · 1 shared paper, 2026 · strength 0.23
  18. Tomoharu Yoshizumi · 1 shared paper, 2026 · strength 0.23
  19. Hiroaki Nagano · 1 shared paper, 2026 · strength 0.23
  20. Susumu Eguchi · 1 shared paper, 2026 · strength 0.23
  21. Hirokazu Noshirο · 1 shared paper, 2026 · strength 0.23
  22. Hiroto Matsui · 1 shared paper, 2026 · strength 0.23
  23. Hirohisa Okabe · 1 shared paper, 2026 · strength 0.23
  24. Takashi Taniguchi · 1 shared paper, 2025 · strength 0.22
  25. Hiroshi Kono · 5 shared papers, 2013–2014 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.